Clinical trials: Patent Ductus Arteriosus (PDA)
Patent Ductus Arteriosus
Assessment of Therapeutic Effect of Rectal Vs. Intravenous Paracetamol in The Treatment of Patent Ductus Arteriosus (PDA) in Neonates
To compare the effectiveness of rectal vs. intravenous paracetamol in the medical treatment of significant PDA in neonates.
- Trial name
- NCT06256211
- Testing
- Paracetamol
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Soha mahmoud Hussien mahdy
Patent Ductus Arteriosus
International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial
The three options for the treatment of patent ductus arterioles (PDA) in preterm infants are conservative approach, pharmacological intervention and surgical ligation.
- Trial name
- NCT02910609
- Testing
- Echocardiography
- Volunteers
- 1,000 people
- Sponsor
- Ankara University
Shock, Preterm Birth Complication
Early Hydrocortisone Versus Regular Treatment in Shock in Extremely Preterm Neonates - an Open Randomized Controlled Trial
The goal of this clinical trial is to determine the effectiveness of early use of hydrocortisone (since the diagnosis of shock) for its resolution within the first 72 hours in premature infants under 1,500 g.
- Conditions
- Shock, Preterm Birth Complication, Preterm Intraventricular Hemorrhage, Asphyxia Perinatal
- Trial name
- NCT07248761
- Testing
- Intravascular Hydrocortisone (stress dosage): 1 mg/k/dose each 8 hours for 5 days, Vasoactive drug therapies
- Where
- Mexico
- Volunteers
- 76 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Patent Ductus Arteriosus
Nitric Oxide, Endothelin-1, and the Patency of Ductus Arteriosus in Preterm Infants
BACKGROUND Patent ductus arteriosus (PDA) is a frequent clinical event in preterm infant. The cardiopulmonary functions of these preterm babies may be adversely affected by the patency of ductus arteriosus.
- Trial name
- NCT00162903
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Patent Ductus Arteriosus, Neonate
Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus
Patent ductus arteriosus or PDA is a blood vessel that connects the right and left side of the heart that usually closes after birth but remains open in some premature infants born before 30 weeks' gestation.
- Trial name
- NCT03103022
- Testing
- Acetaminophen, ibuprofen
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Patent Ductus Arteriosus
Post Marketing Clinical Follow Up Study to Evaluate Efficacy and Safety of the Occlutech PDA Occluder in Patients With Patent Ductus Arteriosus Defects
This retrospective and prospective, multicenter, international post marketing follow up study evaluates the safety and efficacy of the Occlutech® PDA Occluder, delivered using the Occlutech Occlusions Pusher (OOP), in subjects…
- Trial name
- NCT05264753
- Testing
- Occlutech® PDA Occluder
- Where
- 15 sites in Canada, France and 7 more
- Volunteers
- 255 people
- Sponsor
- Occlutech International AB
Patent Ductus Arteriosus
PAIR (Paracetamol and Ibuprofen Research) Pilot Trial
Presence of Patent Ductus Arteriosus is detrimental to an infant born prematurely. The primary objective is to study the efficacy of Paracetamol (proposed new treatment) in treating haemodynamic significant Patent Ductus…
- Trial name
- PAIR (NCT04986839)
- Testing
- Paracetamol injection, Ibuprofen injection
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Manchester University NHS Foundation Trust
Ductus Arteriosus
The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Preterm Birth
Preterm birth still remains a major cause of perinatal morbidity and mortality worldwide. The exact mechanism stimulating term and preterm births in humans is still unknown.
- Trial name
- NCT03073512
- Testing
- Ultrasound examination
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Unity Health Toronto
Patent Ductus Arteriosus After Premature Birth, Patent Ductus Arteriosus Conservative Management
Oral Ibuprofen Versus Placebo in Treatment of Patent Ductus Arteriosus (PDA)in Preterm Infants
The management options of Patent Ductus Arteriosus are still controversial and differ between centers. Recently, conservative management has been gaining interest as the evidence of benefit from medical treatment in terms of…
- Trial name
- NCT05493540
- Testing
- Ibuprofen oral suspension
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Nada Youssef
Ductus Arteriosus, Patent
Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies
Premature babies are affected by a condition known as "patent ductus arteriosus" in which the ductus arteriosus (a normal structure) fails to close after birth as it should.
- Trial name
- NCT00725647
- Volunteers
- 102 people
- Sponsor
- St George's, University of London
Patent Ductus Arteriosus (PDA)
Nit-Occlud PDA Post-Approval Study
The Nit-Occlud PDA Post-Approval Study is designed to continue to evaluate the safety and effectiveness of the device in the post-approval phase.
- Trial name
- NCT02100683
- Testing
- PDA Coil
- Where
- 11 sites in United States
- Volunteers
- 184 people
- Sponsor
- PFM Medical, Inc
Infant, Premature, Ductus Arteriosus, Patent
Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 Weeks
The aim of the study was to evaluate BNP in preterm infants < 28 weeks on the second day of life, when it is still unknown, if a patent ductus arteriosus is hemodynamic significant or not.
- Conditions
- Infant, Premature, Ductus Arteriosus, Patent, Natriuretic Peptide Brain
- Trial name
- NCT00528736
- Where
- Germany
- Volunteers
- 82 people
- Sponsor
- Charite University, Berlin, Germany
Patent Ductus Arteriosus
AMPLATZER Duct Occluder II Additional Sizes
The ADO II AS Study is a single arm, prospective, multicenter, nonrandomized clinical investigation to characterize the safety and effectiveness of the ADO II AS device in patients with a patent ductus arteriosus (PDA).
- Trial name
- ADO II AS (NCT03055858)
- Testing
- ADO II AS (PDA closure)
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices
Patent Ductus Arteriosus
AMPLATZER Duct Occluder II Clinical Study
The objective of this study is to investigate the safety and effectiveness of the ADO II in patients with a PDA.
- Trial name
- ADO II (NCT00713700)
- Testing
- AMPLATZER Duct Occluder II
- Where
- 25 sites in United States
- Volunteers
- 192 people
- Sponsor
- Abbott Medical Devices
Patent Ductus Arteriosus, Patent Ductus Arteriosus - Delayed Closure
Timing of Surgical PDA Ligation and Neonatal Outcomes
Patent ductus arteriosus (PDA) is common among very preterm infants. If pharmacological closure is ineffective or contraindicated, surgical ligation may be required.
- Conditions
- Patent Ductus Arteriosus, Patent Ductus Arteriosus - Delayed Closure, Patent Ductus Arteriosus After Premature Birth
- Trial name
- NCT04126512
- Testing
- PDA ligation
- Where
- 2 sites in Italy, United Kingdom
- Volunteers
- 78 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Apnea of Prematurity, Preterm Birth
Hemodynamic Responses to Cardio-respiratory Events in Preterm Infants
Intermittent episodes of hypoxemia and/or bradycardia, also defined as cardio-respiratory events (CRE) are very frequent in preterm infants and may result in transient hypoxia and hypoperfusion of target organs, with possible…
- Conditions
- Apnea of Prematurity, Preterm Birth, Patent Ductus Arteriosus, Hypoxia, Brain
- Trial name
- NCT04184245
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Coronary Artery Disease, Acute Myocardial Infarction
Heart Cycle Prestudy
In this Prestudy which will be followed by the multicentral GEx- main-trial, the feasibility of a new cardiac rehabilitation device (GEx system) is proved with coronary heart disease patients who participate in cardiac…
- Trial name
- PreGEx (NCT01627457)
- Testing
- Guided Exercise (GEx) system
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- RWTH Aachen University
Patent Ductus Arteriosus
Safety and Efficacy of Ibuprofen in Term Newborns With Patent Ductus Arteriosus (PDA)
The aim of current study is to evaluate the efficacy and safety of oral Ibuprofen in term 20-28 days old newborn referred to Bandarabbas children' hospital in 2011.
- Trial name
- NCT01511887
- Testing
- Oral Ibuprofen
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Hormozgan University of Medical Sciences
Patent Ductus Arteriosus
Paracetamol and Patent Ductus Arteriosus (PDA)
The investigators propose that paracetamol will be similarly effective to ibuprofen in treating PDA in the premature neonate, with fewer side effects.
- Trial name
- NCT01291654
- Testing
- Paracetamol, NSAID, D5W
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Shaare Zedek Medical Center
Persistent Ductus Arteriosus
The Best Treatment Strategy: Surgical vs Pharmacological to Close the Ductus Arteriosus Persistent in Preterm Infants
The decision to treat patent ductus arteriosus in preterm infants, varies from a conservative, medical or immediate surgical treatment; although, at present, there is some controversy about this decision.
- Trial name
- NCT02602054
- Testing
- Surgical treatment, Control group
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Hospital General Naval de Alta Especialidad - Escuela Medico Naval